{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T19:36:53Z","timestamp":1747165013041,"version":"3.40.5"},"reference-count":27,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["jidonline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Investigative Dermatology"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.jid.2023.10.011","type":"journal-article","created":{"date-parts":[[2023,11,3]],"date-time":"2023-11-03T08:37:29Z","timestamp":1699000649000},"page":"855-861.e1","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Changes to Registered and Pivotal Clinical Trials after the 2011 Tri-Societies Guidelines for Clinical Endpoints and Response Criteria in Mycosis Fungoides and S\u00e9zary Syndrome"],"prefix":"10.1016","volume":"144","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7125-9296","authenticated-orcid":false,"given":"Simon J.","family":"Gunter","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9099-7614","authenticated-orcid":false,"given":"Ellen J.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jid.2023.10.011_bib1","doi-asserted-by":"crossref","first-page":"e184","DOI":"10.1371\/journal.pmed.0040184","article-title":"Factors associated with findings of published trials of drug\u2013drug comparisons: why some statins appear more efficacious than others","volume":"4","author":"Bero","year":"2007","journal-title":"PLoS Med"},{"year":"2022","series-title":"Improving public access to aggregate analysis of ClinicalTrials.gov","key":"10.1016\/j.jid.2023.10.011_bib2"},{"key":"10.1016\/j.jid.2023.10.011_bib3","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/s41572-021-00296-9","article-title":"Cutaneous T cell lymphoma","volume":"7","author":"Dummer","year":"2021","journal-title":"Nat Rev Dis Primers"},{"year":"2018","series-title":"Step 3: clinical research","key":"10.1016\/j.jid.2023.10.011_bib4"},{"year":"2023","series-title":"Clinical trials guidance documents","key":"10.1016\/j.jid.2023.10.011_bib5"},{"year":"2023","series-title":"FDALabel: full-text search of drug product labeling","key":"10.1016\/j.jid.2023.10.011_bib6"},{"year":"2023","series-title":"Oncology (cancer)\/hematologic malignancies approval notifications","key":"10.1016\/j.jid.2023.10.011_bib7"},{"key":"10.1016\/j.jid.2023.10.011_bib8","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.1001\/jama.2011.769","article-title":"Characteristics of clinical trials to support approval of orphan vs nonorphan drugs for cancer","volume":"305","author":"Kesselheim","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.jid.2023.10.011_bib9","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1001\/jamadermatol.2022.2749","article-title":"Efficacy and safety of topical hypericin photodynamic therapy for early-stage cutaneous T-cell lymphoma (mycosis fungoides): The FLASH phase 3 randomized clinical trial","volume":"158","author":"Kim","year":"2022","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jid.2023.10.011_bib10","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1016\/S1470-2045(18)30379-6","article-title":"Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial [published correction appears in Lancet Oncol 2018;19:e581]","volume":"19","author":"Kim","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jid.2023.10.011_bib11","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2015-009758","article-title":"Clinical trial registration, reporting, publication and FDAAA compliance: a cross-sectional analysis and ranking of new drugs approved by the FDA in 2012","volume":"5","author":"Miller","year":"2015","journal-title":"BMJ Open"},{"year":"2022","series-title":"National Cancer Institute thesaurus","key":"10.1016\/j.jid.2023.10.011_bib12"},{"year":"2021","series-title":"NCCN guidelines for patients. Primary cutaneous lymphomas","key":"10.1016\/j.jid.2023.10.011_bib13"},{"key":"10.1016\/j.jid.2023.10.011_bib14","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1200\/JCO.2010.32.0630","volume":"29","author":"Olsen","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jid.2023.10.011_bib15","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1182\/blood.2021012057","article-title":"Primary cutaneous lymphoma: recommendations for clinical trial design and staging update from the ISCL, USCLC, and EORTC","volume":"140","author":"Olsen","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.jid.2023.10.011_bib16","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/S0140-6736(17)31266-7","article-title":"Brentuximab vedotin or physician\u2019s choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial","volume":"390","author":"Prince","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.jid.2023.10.011_bib17","doi-asserted-by":"crossref","first-page":"7539","DOI":"10.1200\/JCO.2019.37.15_suppl.7539","article-title":"Time to next treatment in patients with previously treated cutaneous T-cell lymphoma (CTCL) receiving mogamulizumab or vorinostat: a MAVORIC post-hoc analysis","volume":"37","author":"Pro","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jid.2023.10.011_bib18","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1093\/annonc\/mdx352","article-title":"Global patterns of care in advanced stage mycosis fungoides\/Sezary syndrome: a multicenter retrospective follow-up study from the Cutaneous Lymphoma International Consortium","volume":"28","author":"Quaglino","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jid.2023.10.011_bib19","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1056\/NEJMoa2021436","article-title":"Dexamethasone in hospitalized patients with Covid-19","volume":"384","author":"Horby","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jid.2023.10.011_bib20","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1111\/bjd.18541","article-title":"Evaluation of haematopoietic stem cell transplantation in patients diagnosed with cutaneous T-cell lymphoma at a tertiary care centre: should we avoid chemotherapy in conditioning regimes?","volume":"182","author":"Ritchie","year":"2020","journal-title":"Br J Dermatol"},{"year":"2022","series-title":"RStudio: integrated development environment for R","key":"10.1016\/j.jid.2023.10.011_bib21"},{"key":"10.1016\/j.jid.2023.10.011_bib22","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1111\/bjh.17117","article-title":"The changing therapeutic landscape, burden of disease, and unmet needs in patients with cutaneous T-cell lymphoma","volume":"192","author":"Scarisbrick","year":"2021","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jid.2023.10.011_bib23","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1038\/s41587-022-01630-6","article-title":"Fresh from the biotech pipeline: fewer approvals, but biologics gain share","volume":"41","author":"Senior","year":"2023","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.jid.2023.10.011_bib24","doi-asserted-by":"crossref","first-page":"k1452","DOI":"10.1136\/bmj.k1452","article-title":"How to avoid common problems when using\u00a0ClinicalTrials.gov in research: 10 issues to consider","volume":"361","author":"Tse","year":"2018","journal-title":"BMJ"},{"key":"10.1016\/j.jid.2023.10.011_bib25","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1182\/blood-2018-11-881268","article-title":"The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas [published correction appears in Blood 2019;134:1112]","volume":"133","author":"Willemze","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.jid.2023.10.011_bib26","doi-asserted-by":"crossref","first-page":"iv30","DOI":"10.1093\/annonc\/mdy133","article-title":"Primary cutaneous lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"29","author":"Willemze","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jid.2023.10.011_bib27","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.3284","article-title":"Assessment of clinical trials supporting US Food and Drug Administration approval of novel therapeutic agents, 1995\u20132017","volume":"3","author":"Zhang","year":"2020","journal-title":"JAMA Netw Open"}],"container-title":["Journal of Investigative Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022202X23030385?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022202X23030385?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,6]],"date-time":"2025-04-06T02:21:06Z","timestamp":1743906066000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022202X23030385"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":27,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["S0022202X23030385"],"URL":"https:\/\/doi.org\/10.1016\/j.jid.2023.10.011","relation":{},"ISSN":["0022-202X"],"issn-type":[{"type":"print","value":"0022-202X"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Changes to Registered and Pivotal Clinical Trials after the 2011 Tri-Societies Guidelines for Clinical Endpoints and Response Criteria in Mycosis Fungoides and S\u00e9zary Syndrome","name":"articletitle","label":"Article Title"},{"value":"Journal of Investigative Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jid.2023.10.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier, Inc. on behalf of the Society for Investigative Dermatology.","name":"copyright","label":"Copyright"}]}}